Correlagen Diagnostics

Competitive Assessment

March 23, 2009

Competitive Assessment• Offerings (Cardiology, Autism, Immunology, Opthalmology)

– Test menu– Test groupings– Proprietary IP

• Commercialization Capabilities– Branding / positioning– Customer relationships– Pricing– Promotional resources– Service effectiveness

• Gene Testing Process– Testing capabilities– Testing quality– Testing Cost

• Resources – Financials– Leadership team

Offerings: CardiologyCDx GeneDx PGx Partners Celera

Test Menu (diseases)

• HCM• DCM

•

Current• Coronary heart disease

Pipeline• KiF-6 – CAD risk assessment• LPA –stroke & MI risk assessment• Stroke• Deep vein thrombosis

Test Panels

Proprietary IP

Offerings: AutismCDx GeneDx Athena Others?

Test Menu (diseases)

• PTEN

Test Panels

Proprietary IP

Offerings: ImmunologyCDx GeneDx Progene XDx

Test Menu (diseases)

•

Test Panels

Proprietary IP

Offerings: OpthalmologyCDx-

OptherionArticDx Retinoblast

omaOther?

Test Menu (diseases)

• • MaculaRisk for AMD

Test Panels

Proprietary IP

Commercialization Capabilities

CDx GeneDx PGx Partners Celera

Branding / Positioning

• “Genetics lab run by geneticists”• Outstanding science; superior educational & clinical support; affordability

Customer Relationships

• Focus on 2,000-2,500 geneticists

• Focus on cardiologists

Pricing

Promotional Resources

• Salesforce began mid-’08, now x reps

• Salesforce of ~20 reps

Service

• TAT of x • TAT of x

Gene Testing ProcessCDx GeneDx PGx Partners Celera

Testing Capabilities

• • DNA sequencing• Gene chip on high resolution constitutional array oligonucleotide platform• Claim to do high-throughput sequencing

Testing “Quality”

Cost

Position

Resources

CDx GeneDx PGx Partners Celera Other?

Financial

• Acquired by BRL for $17m 10/06

• GeneDx Revenues $5.4 (CY’06), $9.9 (FY’07), $17-18(FY’08)• EBITDA >30%

Leadership

• NIH Geneticists